User profiles for WILLIAM TILLETT
Dr William TillettRoyal National Hospital for Rheumatic Diseases Verified email at nhs.net Cited by 3248 |
Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus
WS Tillett, T Francis Jr - The Journal of experimental medicine, 1930 - ncbi.nlm.nih.gov
Sera from individuals acutely ill with lobar pneumonia possess the capacity to precipitate in
high titre a non-protein somatic fraction derived from pneumococci (Fraction C). Following …
high titre a non-protein somatic fraction derived from pneumococci (Fraction C). Following …
The fibrinolytic activity of hemolytic streptococci
WS Tillett, RL Garner - The Journal of experimental medicine, 1933 - rupress.org
Broth cultures of hemolytic streptococci derived from patients are capable of rapidly liquefying
normal human fibrin clot. The active fibrinolytic principle is also contained in sterile, cell-…
normal human fibrin clot. The active fibrinolytic principle is also contained in sterile, cell-…
[PDF][PDF] The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural …
WS Tillett, S Sherry - The Journal of clinical investigation, 1949 - Am Soc Clin Investig
… By WILLIAM S. TILLETT AND SOL SHERRY (From the Department of Medicine, New
York University College of Medicine, and the Third … Review article for references up to …
York University College of Medicine, and the Third … Review article for references up to …
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
…, P Zueger, AL Pangan, W Tillett - Annals of the …, 2021 - ard.bmj.com
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials
Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA)
clinical trials that represent both patients' and physicians' priorities. Methods We …
clinical trials that represent both patients' and physicians' priorities. Methods We …
Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis
Objective To identify predictors of poorer physical function in established psoriatic arthritis (PsA).
Methods PsA patients with disease duration of ≥10 years were identified from the Bath …
Methods PsA patients with disease duration of ≥10 years were identified from the Bath …
The ClASsification for Psoriatic ARthritis (CASPAR) criteria–a retrospective feasibility, sensitivity, and specificity study
Objective. To evaluate the sensitivity, specificity, and feasibility of the ClASsification criteria
for Psoriatic ARthritis (CASPAR) to retrospectively classify an existing research cohort. …
for Psoriatic ARthritis (CASPAR) to retrospectively classify an existing research cohort. …
Psoriatic arthritis
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features,
which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests …
which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests …
Work disability in psoriatic arthritis: a systematic review
W Tillett, C de-Vries, NJ McHugh - Rheumatology, 2012 - academic.oup.com
Objective. Work disability (WD) is an important functional outcome measure in arthritis. There
is a large body of information on WD in rheumatic diseases such as RA and AS; however, …
is a large body of information on WD in rheumatic diseases such as RA and AS; however, …
[HTML][HTML] Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 …
…, EL McDearmon-Blondell, AL Pangan, W Tillett - Rheumatology and …, 2021 - Springer
Introduction Upadacitinib is a Janus kinase inhibitor under investigation in patients with
psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in …
psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in …